S100B and Miyoshi myopathy: S100B(ββ) is a clinically validated marker for malignant melanoma (elevated only in tumours) [19,20] and traumatic brain injury (TBI) [21,22,23] and has been associated with cancer progression in multiple myeloma (MM), NSCLC/SCLC, pancreatic cancer, etc., making it a potential target [24,25,26,27,28].